港股早評:三大指數大幅低開,科技股、醫藥股、蘋果概念股跌幅明顯
關稅衝擊猛烈,隔夜美股衝高回落,中概指數續跌5.05%。港股三大指數大幅低開,恆指跌3.14%,國指跌3.13%,恆生科技指數跌4.26%。盤面上,大型科技股全線下挫,百度跌5.6%,京東跌5.45%,阿里巴巴跌近5%,美團、騰訊、小米均走低;特朗普稱美國將對藥品徵收關稅,生物醫藥股大肆下挫,康龍化成大跌超13%,泰格醫藥大跌超11%,再鼎醫藥、凱萊英、信達生物皆下挫;美股蘋果大跌近5%,蘋果概念股繼續下跌,汽車股、光伏股、機器人概念股、內險股、家電股齊跌。另一方面,防守板塊軍工股、農業股逆勢上漲,中船防務大漲近9%,十月稻田漲近7%,豬肉概念股中糧家佳康漲2.6%。(格隆匯)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.